- AU$541.10m
- AU$422.86m
- AU$190.31m
- 65
- 56
- 94
- 81
Annual income statement for Mayne Pharma, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
R2019 June 30th | 2020 June 30th | 2021 June 30th | R2022 June 30th | 2023 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 526 | 458 | 401 | 158 | 190 |
| Cost of Revenue | |||||
| Gross Profit | 316 | 212 | 183 | 75.2 | 90.4 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 880 | 593 | 665 | 303 | 460 |
| Operating Profit | -354 | -135 | -264 | -146 | -270 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -354 | -135 | -264 | -146 | -270 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -279 | -96.2 | -209 | -220 | -317 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -279 | -92.8 | -208 | -281 | 117 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -279 | -92.8 | -208 | -281 | 117 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.407 | -0.29 | -0.569 | -1.9 | -3.19 |
| Special Dividends per Share |